F-1/A: Living Homeopathy Files F-1/A for Nasdaq IPO

Living Homeopathy International Ltd. files an amended F-1 registration statement for its proposed Nasdaq Capital Market IPO of 1,250,000 Class A Ordinary Shares, highlighting its leading market share in Hong Kong's homeopathy sector amidst regulatory uncertainties.

Summary

• Living Homeopathy International Ltd. is pursuing an Initial Public Offering (IPO) of 1,250,000 Class A Ordinary Shares on the Nasdaq Capital Market, with an estimated price range of $4.0 to $6.0 per share.
• The underwriters have a 45-day over-allotment option to purchase up to an additional 15% (187,500) Class A Ordinary Shares.
• The company expects to receive net proceeds of approximately $4.07 million from the offering (or $5.00 million if the over-allotment option is fully exercised).
• Proceeds are planned to be used for advertising (40%), market and product development/marketing (30%), and working capital/general corporate purposes (30%).
• Living Homeopathy is a Hong Kong-based homeopathy service provider, holding the largest market share of approximately 35.8% in Hong Kong's homeopathy product sales revenue in 2024.
• Total net revenue decreased by 1.0% to $8,422,639 for the fiscal year ended March 31, 2025, from $8,510,216 in the prior year, primarily due to a 55.1% decrease in sales of water filters and related products.
• Net income increased by 7.8% to $812,130 for the fiscal year ended March 31, 2025, from $753,429 in the prior year.
• Gross profit increased by $42,436 to $6,423,394 in fiscal year 2025, with the gross margin improving from 75.0% to 76.3%.
• Operating expenses increased by 6.9% to $5,833,144 in fiscal year 2025, largely driven by a 4,444.2% increase in legal and professional fees and an 86.8% increase in other general and administrative expenses, primarily due to IPO-related costs and event fees.
• Cash dividends of $983,560 and $325,078 were declared during the fiscal years ended March 31, 2025 and 2024, respectively.
• Mr. Ka Lun To, the Chairman and Chief Executive Officer, will retain significant control, holding approximately 49.43% of the total voting power post-IPO (assuming no over-allotment).

Sentiment

Score: 6

Explanation: The company is pursuing a significant IPO and holds a leading market position in Hong Kong's homeopathy sector, demonstrating improved net income and gross margin, and strong operating cash flow. However, the slight revenue decline, substantial IPO-related expenses, and significant geopolitical and regulatory uncertainties associated with Hong Kong and mainland China temper the overall positive outlook. The considerable dilution for new investors also presents a notable concern.

Positives

• Ranked first in the Hong Kong homeopathy market by market share of approximately 35.8% in terms of homeopathy product sales revenue generated in Hong Kong in 2024.
• Offers a diversified product portfolio including homeopathic remedies, co-remedies, classical flower remedies, personal care products, and water filters.
• Maintains established quality control practices, including third-party product testing by Hong Kong STC, which is not a regulatory requirement but a quality assurance step.
• Has long-term business relationships (over a decade with majority of top 5 suppliers) ensuring continuity of product supply.
• Possesses experienced management and a large network of 687 practitioners (employees and non-employee participants in the mentor-mentee program) holding Homeopathy First Aid Certificates.
• Net income increased by 7.8% from $753,429 in fiscal year 2024 to $812,130 in fiscal year 2025.
• Gross margin improved from 75.0% in fiscal year 2024 to 76.3% in fiscal year 2025.
• Net cash generated from operating activities significantly increased from $687,495 in fiscal year 2024 to $1,463,328 in fiscal year 2025.
• Discharged all bank borrowings in August 2024, improving the balance sheet liquidity.
• Net current assets increased by 69.4% from $948,686 in fiscal year 2024 to $1,579,847 in fiscal year 2025.

Negatives

• Total net revenue decreased by 1.0% in fiscal year 2025, primarily due to a 55.1% decrease in sales of water filters and related products.
• Operating expenses increased by 6.9% in fiscal year 2025, largely due to a 4,444.2% increase in legal and professional fees and an 86.8% increase in other general and administrative expenses, primarily related to IPO costs and event fees.
• Relies on a limited number of suppliers, with three suppliers accounting for approximately 37%, 25%, and 21% of total purchases in fiscal year 2025.
• Lack of written contracts with suppliers reduces predictability in procurement and may complicate breach of contract claims.
• Does not anticipate paying any cash dividends to U.S. investors in the foreseeable future, as earnings will be reinvested for business expansion.
• New investors purchasing Class A Ordinary Shares in the offering will experience immediate and substantial dilution of approximately $4.32 per share.
• The company does not maintain business interruption insurance or product liability insurance, which could expose it to significant costs and business disruption in case of unforeseen events.

Risks

• Operating in a competitive and rapidly evolving industry makes it difficult to evaluate prospects and effectively manage growth.
• Unfavorable publicity or consumer acceptance of homeopathy or specific products (e.g., LIVING Colloidal Silver) could reduce sales and damage reputation.
• The business is heavily regulated, and the industry may face increasingly tightened regulatory requirements and scrutiny in Hong Kong and new markets like mainland China.
• Potential product liability, false marketing, or other consumer claims could lead to substantial liabilities and regulatory penalties.
• Risk of enforcement action if employees or mentor-mentee program participants engage in improper marketing or promotion.
• The sustainability of the mentor-mentee program relies on strict compliance with internal codes and relevant laws, particularly regarding 'Pyramid Scheme' regulations.
• Product recalls could incur significant and unexpected costs and damage reputation.
• May require substantial additional funding in the future, with no assurance that additional financing will be available on reasonable terms.
• Damage to the reputation of brands could adversely affect the business.
• Increases in labor costs in Hong Kong and non-compliance with employment and labor protection laws may adversely affect operations.
• Failure to manage and expand relationships with suppliers, or procure products at favorable terms, could harm business and growth prospects.
• Substantial supplier concentration with a limited number of suppliers poses risks if relationships change or difficulties arise.
• Lack of written contracts with suppliers reduces procurement predictability and flexibility.
• Business depends on the continued efforts of senior management; loss of key executives could severely disrupt operations.
• Directors, management, and shareholders may be subject to negative publicity, claims, controversies, lawsuits, or other legal/administrative proceedings.
• Reliance on proprietary information (trade secrets, know-how) without statutory protection in Hong Kong makes enforcement difficult.
• Risk of being accused of infringing intellectual property rights of others.
• Proper functioning of information technology systems is essential; failure to maintain satisfactory performance could adversely affect business.
• Improper use, disclosure, or unauthorized access to collected data could harm reputation.
• Subject to complaints, claims, controversies, regulatory actions, arbitrations, and legal proceedings, which could incur substantial costs and divert management attention.
• Lack of insurance (business interruption, product liability, key man life insurance, IT systems) could expose the company to significant costs and business disruption.
• Financial and operating performance may be adversely affected by epidemics, natural disasters, and other catastrophes.
• Directors, officers, and Class B shareholders currently control a significant percentage (91.09% post-IPO) of total voting power, potentially limiting influence of other shareholders.
• Difficulties in protecting interests and enforcing rights through U.S. courts due to incorporation under Cayman Islands law.
• Limited shareholder rights to convene general meetings or present proposals under Cayman Islands law.
• Directors are not subject to a term of office, making removal potentially difficult.
• Reliance on dividends and other distributions from the Hong Kong subsidiary to fund cash and financing requirements, with potential limitations on fund transfers.
• Lack of effective internal controls over financial reporting may affect ability to accurately report financial results or prevent fraud.
• Risk of ceasing to qualify as a foreign private issuer, leading to increased compliance costs.
• Incurring increased costs as a public company, particularly after ceasing to qualify as an emerging growth company.
• Board of directors may decline to register transfers of Class A Ordinary Shares in certain circumstances (though unlikely to affect market transactions).
• Cayman Islands economic substance requirements may have an effect on business and operations.
• PRC government may exercise significant oversight and discretion over Hong Kong operations, potentially intervening or influencing business, or imposing restrictions on fund transfers.
• The enactment of the Hong Kong National Security Law could impact the Hong Kong subsidiary.
• Political risks associated with conducting business in Hong Kong.
• Uncertainties regarding future requirements to obtain approvals from mainland China and Hong Kong authorities for U.S. listing.
• More stringent requirements for sharing business and accounting records with foreign auditing firms (Archives Rules) could hinder ability to offer securities.
• Difficulty for overseas shareholders and/or regulators to conduct investigations or collect evidence within mainland China.
• Additional costs and procedural obstacles in effecting service of legal process, enforcing foreign judgments, or bringing actions in Hong Kong.
• Business may be affected by the currency peg system in Hong Kong.
• No public market for Class A Ordinary Shares prior to this offering, potentially leading to thin trading and volatility.
• Although the audit report is prepared by U.S. auditors subject to PCAOB inspections, future regulatory changes or obstructions could lead to delisting under the HFCA Act.
• Recent joint statements by the SEC, proposed Nasdaq rule changes, and U.S. legislation call for more stringent criteria for emerging market companies, adding uncertainties.
• Nasdaq may apply additional and more stringent criteria for initial and continued listing due to small public offering size and large insider holdings.
• Extreme stock price volatility unrelated to actual operating performance, making valuation difficult.
• If securities or industry analysts do not publish research or adversely change recommendations, share price and trading volume could decline.
• Substantial future sales or perceived potential sales of Class A Ordinary Shares could cause the price to decline.
• Need for additional capital may result in further dilution or increased debt service obligations.
• Emerging growth company status allows reduced reporting requirements, potentially making comparisons with other public companies difficult.
• Foreign private issuer status means disclosure obligations differ from U.S. domestic reporting companies.
• Management has no prior experience in managing and operating a public company, requiring substantial time for compliance initiatives.
• If financial condition deteriorates, may not meet continued listing standards on the Nasdaq Capital Market.
• Undetermined use of a portion of the IPO proceeds, giving management broad discretion.
• Risk of being classified as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, leading to adverse consequences for U.S. Holders.

Future Outlook

The company plans to diversify its sales channels by developing an online flagship store on Tmall Global to sell homeopathic co-remedies to consumers in mainland China. It is committed to promoting the regularization and standardization of the homeopathy market in Hong Kong and mainland China by collaborating with regional homeopathy-related institutes and medical schools. The company intends to retain all future earnings for business expansion and does not anticipate paying cash dividends to U.S. investors in the foreseeable future.

Management Comments

• We believe that we may leverage this established market share to enhance the market influence of our brand name to further attract customer attention and increase our sales.
• We have not entered into written contracts with our suppliers, which in our commercial judgment relieves us from a binding minimum procurement amount requirement associated with written contracts with our suppliers and gives us more flexibility if we decide to replace any existing suppliers with new suppliers that can better suit our business needs.
• We currently intend to retain all available funds and future earnings, if any, for the operation and expansion of our business and do not anticipate declaring or paying any dividends in the foreseeable future.
• We believe that our existing resources, including cash generated from operations, will be sufficient to meet our working capital requirement for our current operating and capital expenditure needs and obligations over the next twelve months.

Industry Context

The Traditional and Complementary Medicine (T&CM) market in Hong Kong has shown robust growth, expanding from $176 million in 2019 to $309.4 million in 2023 (15.1% CAGR), with projections to reach $1,299.1 million by 2029 (25.3% CAGR from 2024-2028). The specific homeopathy market in Hong Kong grew from $16.6 million in 2019 to $20 million in 2023 (4.8% CAGR), and is forecasted to reach $42.9 million by 2029 (12.0% CAGR from 2024-2028). Key growth drivers for T&CM include the rising prevalence of chronic diseases, an increasing aging population, and enhancing cultural acceptance. The homeopathy market is driven by increasing demand for naturally sourced products, higher adoption rates due to rising medical costs and health awareness, and expansion of product portfolios by key players. Future trends include increased regulation and standardization, and greater investment in research and clinical validation. Entry barriers for the homeopathy market are significant, including abundant capital, the need for strong brand reputation and customer loyalty, difficulty in attracting experienced professionals, the necessity of management and operating experience, and complex regulatory compliance. The Hong Kong homeopathy market is highly concentrated.

Comparison to Industry Standards

• The company is ranked first in the Hong Kong homeopathy market by market share of approximately 35.8% in terms of homeopathy product sales revenue generated in Hong Kong in 2024, according to Frost & Sullivan, indicating a strong competitive position.
• The Hong Kong homeopathy market is highly concentrated, with the company identified as one of the few key players, alongside competitors such as HomeoCare HK, Vitality Centre, Integrated Medicine Institute, and Maya Health Institute.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any legal proceedings that, in management's opinion, would have a material adverse effect on the business, financial condition, operating results, or cash flows.
• May become involved in legal proceedings or be subject to claims arising in the ordinary course of business.
• Faces potential product liability, false marketing, or other consumer claims, which could result in substantial liabilities and regulatory penalties.
• Could face regulatory actions or other sanctions from the CSRC, CAC, or other PRC or Hong Kong regulatory authorities if future permissions or approvals are required or if applicable laws, regulations, or interpretations change and compliance is not met.

Related Party Transactions

• Sales of healthcare products, personal care products, and water filters and related products to Living Homeopathy Limited (Macau), an entity controlled by Mr. To: $390,842 in FY2025 and $368,969 in FY2024.
• Purchases of certain healthcare products from Living Homeopathy Limited (Macau): $417,843 in FY2025 and $456,773 in FY2024.
• Lease expense with Silver Link Limited, an entity controlled by Mr. To, for office premises: $184,780 in FY2025 and $184,036 in FY2024.
• Transfer of ownership of land and building from Living HK to Mr. To: $1,962,362 in FY2025, which resulted in a net decrease of $38,831 in the amount due from shareholder after accounting for stamp duty paid on Mr. To's behalf.
• Discharge of bank borrowings of $2,162,619 to Mr. To in August 2024, as Mr. To obtained a property installment loan in his name to settle Living HK's bank borrowings.
• Amount due to Ms. Hung (a shareholder): $924,241 as of March 31, 2025, which is interest-free, unsecured, and repayable on demand, mainly to finance IPO-related expenses.

Stakeholder Impact

• Shareholders: New investors face significant immediate dilution. Existing Class B shareholders, particularly Mr. To, will retain substantial voting control (approx. 49.43% for Mr. To, 91.09% for directors/officers/Class B shareholders combined post-IPO). No cash dividends are anticipated in the foreseeable future, meaning returns will depend on share price appreciation. Share value is highly susceptible to regulatory and geopolitical risks related to Hong Kong and mainland China.
• Employees: The company offers a dynamic work environment, competitive salaries, performance-based cash bonuses, and other incentives. All employees are members of the mentor-mentee program, which provides opportunities for training and sales commissions.
• Customers: The company aims to provide quality homeopathy resources and products. Customer acceptance and sales could be negatively impacted by unfavorable publicity, product liability claims, or changes in regulatory scrutiny.
• Suppliers: The company maintains long-term relationships with key suppliers, but the lack of written contracts introduces uncertainty regarding procurement terms and potential disputes.
• Creditors: The company has discharged its bank borrowings, reducing debt obligations. Future financing needs may lead to new debt or equity issuances.

Next Steps

• Proposed listing of Class A Ordinary Shares on the Nasdaq Capital Market, contingent upon final Nasdaq listing approval.
• Diversify sales channels by developing an online flagship store on Tmall Global to sell homeopathic co-remedies to consumers in mainland China.
• Promote market regularization and standardization of the homeopathy market in Hong Kong and mainland China by working with regional homeopathy-related institutes, medical schools, and other organizations.
• Management will have significant flexibility and broad discretion in applying the net proceeds from the offering.
• The company will incur increased costs as a public company, particularly after it ceases to qualify as an emerging growth company.
• The company will be subject to periodic reporting and other informational requirements of the Exchange Act as a foreign private issuer.

Key Dates

Recommendation

The company holds a leading market position in Hong Kong's homeopathy sector and has demonstrated improved net income and gross margin, along with strong operating cash flow. The IPO aims to fund strategic growth initiatives, including market and product development. However, the recent decline in overall revenue, the significant increase in operating expenses due to IPO-related costs, and the substantial geopolitical and regulatory uncertainties associated with operating in Hong Kong and expanding into mainland China introduce considerable risk. The high dilution for new investors and the concentrated voting power with existing insiders also warrant caution. Given these mixed signals and the inherent risks of a new public offering from a region with evolving regulatory landscapes, a 'Hold' recommendation is appropriate for investors to monitor the company's adaptation to public market demands and the unfolding geopolitical environment before making further investment decisions.

Keywords

Homeopathy, Hong Kong, Healthcare Products, IPO, Nasdaq Capital Market, SEC Filing, F-1/A, Alternative Medicine, Wellness, Financial Performance, Regulatory Risk, China Relations, Emerging Growth Company, PCAOB, Market Share, Corporate Governance